par Kendler, David;Body, Jean-Jacques 
;Brandi, M.L.;Broady, Raewyn;Cannata-Andía, Jorge J.B.;Cannata-Ortiz, Jimena M.J.;El Maghraoui, Abdellah;Guglielmi, Giuseppe;Hadji, Peyman;Pierroz, Dominique;De Villiers, Tobie;Ebeling, Peter R;Rizzoli, René
Référence Journal of Bone Oncology, 28, 100361
Publication Publié, 2021-06
;Brandi, M.L.;Broady, Raewyn;Cannata-Andía, Jorge J.B.;Cannata-Ortiz, Jimena M.J.;El Maghraoui, Abdellah;Guglielmi, Giuseppe;Hadji, Peyman;Pierroz, Dominique;De Villiers, Tobie;Ebeling, Peter R;Rizzoli, RenéRéférence Journal of Bone Oncology, 28, 100361
Publication Publié, 2021-06
Article révisé par les pairs
| Résumé : | Background: Treatment advances have reduced the adverse events associated with hematopoietic stem cell transplant (HSCT) and led to an increased number of transplants performed. HSCT patients are living longer with concerns on long-term outcomes. Bone fragility and fracture are at the forefront for long-term morbidities post-HSCT. Results: In HSCT recipients, evidence has accumulated to support recommendations for more extensive monitoring of bone fragility and more appropriate administration of osteoporosis pharmacotherapies for patients at high risk of bone loss and/or fracture. Conclusion: This executive summary reports and summarizes the main recommendations published previously, including bone assessment, dietary and lifestyle recommendations and osteoporosis medication. |
